An Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Oral BG9928 in Subjects With Mild and Moderate Hepatic Impairment and in Healthy Subjects

Trial Profile

An Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Oral BG9928 in Subjects With Mild and Moderate Hepatic Impairment and in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Tonapofylline (Primary)
  • Indications Acute heart failure; Chronic heart failure
  • Focus Pharmacokinetics
  • Sponsors Biogen Idec
  • Most Recent Events

    • 24 Dec 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
    • 24 Dec 2009 Actual patient number (23) added as reported by ClinicalTrials.gov.
    • 24 Dec 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top